politics
Fifth Circuit Temporarily Blocks Mail-Order Mifepristone Access
A federal appeals court has blocked the mailing of the abortion pill mifepristone, ending pandemic-era rules and requiring in-person prescriptions. The ruling criticizes the FDA's handling of safety data and sides with pro-life states like Louisiana. The drug's manufacturer has asked the Supreme Court to intervene.
axios.comAudio version
Tap play to generate a narrated version.
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit issued a ruling on Friday that temporarily blocks the mailing of the abortion pill mifepristone nationwide, reinstating an in-person requirement for obtaining the drug. The decision affects rules established by the Food and Drug Administration (FDA) during the COVID-19 pandemic, which had allowed mifepristone to be dispensed through the mail without an in-person visit.
The court's order stems from a lawsuit filed by Louisiana and other states challenging the FDA's 2021 and 2023 actions that permitted mail-order distribution of mifepristone. In its ruling, the panel stated, "Every abortion facilitated by FDA’s action cancels Louisiana’s ban," highlighting that the federal policy allows out-of-state prescribers to provide the drug in ways that conflict with state laws.
Louisiana law recognizes an unborn child as a human being from the moment of conception and bans abortion with limited exceptions for maternal health. In 2024, Louisiana classified mifepristone as a controlled and dangerous substance, becoming the first state to do so.
The Fifth Circuit, based in New Orleans, has jurisdiction over federal cases from Louisiana, Mississippi, and Texas. The panel consists of judges appointed by former Presidents Donald Trump (two) and George W. Bush (one).
Danco Laboratories, the manufacturer of mifepristone, filed an emergency application with the Supreme Court on Saturday to pause the Fifth Circuit's ruling. In the application, Danco's attorneys wrote, "It bears emphasis how unprecedented the Fifth Circuit’s order is," arguing that the nationwide block disrupts access to an FDA-approved medication.
The FDA first approved mifepristone in 2000 under the Clinton administration, and for over two decades, it required in-person dispensing. The agency temporarily lifted this requirement in 2021 citing pandemic conditions and made it permanent in 2023, both under President Joe Biden.
